Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises in Stendörren Fastigheter AB (publ):s issuance and repurchase of bonds
Mandate

Vinge advises in Stendörren Fastigheter AB (publ):s issuance and repurchase of bonds

January 22, 2021 Banking and Finance

Vinge advises in Stendörren’s issuance of a new senior unsecured bond in an amount of SEK 700,000,000 within a framework amount of SEK 1,000,000,000 and in Stendörren’s repurchase of its existing senior unsecured bonds.

The new bonds have a tenor of 3.25 years and carries a floating rate interest of 3 months STIBOR plus 365 basis points. In accordance with the terms and conditions, the new bonds are intended to be listed on the corporate bond list of Nasdaq Stockholm. Nordea Bank Abp and Swedbank AB (publ) acted as arrangers, bookrunners and dealer managers in connection with the transaction. Swedbank AB (publ) also acted as issuing agent.

Vinge’s team consisted of Louise Brorsson Salomon, Lionardo Ojeda and Hannes Pettersson.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025